{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN88", "query": { "intervention": "REGN88" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=REGN88&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-10T19:23:36.021Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01061736", "title": "Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 1675, "start_date": "2010-03", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 45, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Gilbert, Arizona + 39 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01061736" }, { "nct_id": "NCT01764997", "title": "An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Placebo (for sarilumab)", "type": "DRUG" }, { "name": "Placebo (for etanercept)", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 776, "start_date": "2013-04", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2017-07-27", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Glendale, California • Thousand Oaks, California + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "California" }, { "city": "Thousand Oaks", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Victorville", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01764997" }, { "nct_id": "NCT03378219", "title": "An Observational Study on Sarilumab-exposed Pregnancies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis -Exposure During Pregnancy" ], "interventions": [ { "name": "Sarilumab SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 113, "start_date": "2018-05-18", "completion_date": "2024-12-06", "has_results": false, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03378219" }, { "nct_id": "NCT01217814", "title": "Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "methotrexate (MTX)", "type": "DRUG" }, { "name": "Folic/folinic acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 16, "start_date": "2010-11", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 4, "location_summary": "Freehold, New Jersey • New York, New York • Jackson, Tennessee + 1 more", "locations": [ { "city": "Freehold", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01217814" }, { "nct_id": "NCT01768572", "title": "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "tocilizumab", "type": "DRUG" }, { "name": "hydroxychloroquine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "sulfasalazine", "type": "DRUG" }, { "name": "leflunomide", "type": "DRUG" }, { "name": "subcutaneous placebo", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 202, "start_date": "2013-03", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 14, "location_summary": "Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Aventura", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01768572" }, { "nct_id": "NCT01055899", "title": "Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "REGN88", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-07", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 2, "location_summary": "Duncansville, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01055899" }, { "nct_id": "NCT04315298", "title": "Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Sarilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1912, "start_date": "2020-03-18", "completion_date": "2020-09-02", "has_results": true, "last_update_posted_date": "2021-09-23", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 62, "location_summary": "Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04315298" }, { "nct_id": "NCT03564340", "title": "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Ovarian Cancer", "Recurrent Fallopian Tube Cancer", "Recurrent Primary Peritoneal Cancer", "Recurrent Endometrial Cancer", "Endometrial Cancer", "Low-grade Serous Ovarian Cancer" ], "interventions": [ { "name": "Ubamatamab", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" }, { "name": "Sarilumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 890, "start_date": "2018-05-21", "completion_date": "2027-05-10", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564340" }, { "nct_id": "NCT01328522", "title": "Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "SAR153191 (REGN88)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 32, "start_date": "2011-05", "completion_date": "2011-09", "has_results": false, "last_update_posted_date": "2011-10-24", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 4, "location_summary": "Beverly Hills, California • Ocala, Florida • Duncansville, Pennsylvania + 1 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328522" }, { "nct_id": "NCT02017639", "title": "Sarilumab Effect on the Pharmacokinetics of Simvastatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "sarilumab SAR153191 (REGN88)", "type": "DRUG" }, { "name": "simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 19, "start_date": "2014-01", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-04-07", "last_synced_at": "2026-09-10T19:23:36.021Z", "location_count": 3, "location_summary": "Duncansville, Pennsylvania • Jackson, Tennessee • Dallas, Texas", "locations": [ { "city": "Duncansville", "state": "Pennsylvania" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02017639" } ] }